Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial
机构:[1]Lymphoma Research Group, Instituto de Investigación Sanitaria Puerta de HierroSegovia de Arana, Majadahonda, Spain[2]Pathology Service, Hospital del Mar, Barcelona, Spain[3]Pathology Department, Hospital Universitari de Bellvitge-IDIBELL,Bellvitge, Spain[4]Hematology Department, Hospital Universitario Virgen del Rocío,Seville, Spain[5]Research Group in Molecular Cancer Pathology, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Majadahonda, Spain[6]Hematology Service, Hospital del Mar, Barcelona, Spain[7]Pathology Department, HospitalUniversitario Ramón y Cajal, Madrid, Spain[8]Oncology Department, Complejo Hospitalario de Pontevedra, Pontevedra, Spain[9]Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain[10]Department of Oncology, Hospital Clinico SanCecilio, Granada, Spain[11]Clinic Hematology Department, Institut Catala d’OncologiaIDIBELL, Bellvitge, Spain[12]Hematology Department, Hospital Universitario Puerta deHierro, Majadahonda, Spain[13]Pathology Department, Complejo Hospitalario deToledo, Toledo, Spain[14]Servicio de Oncología Médica, Hospital Puerta de HierroMajadahonda, Madrid, Madrid, Spain
第一作者机构:[1]Lymphoma Research Group, Instituto de Investigación Sanitaria Puerta de HierroSegovia de Arana, Majadahonda, Spain
推荐引用方式(GB/T 7714):
I. Fernandez-Miranda,L. Pedrosa,S. Gómez,et al.Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial[J].ANNALS OF ONCOLOGY.2021,32:S775-S776.doi:10.1016/j.annonc.2021.08.124.
APA:
I. Fernandez-Miranda,L. Pedrosa,S. Gómez,J. González-Rincón,B. Espinet...&M. Sánchez-Beato.(2021).Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial.ANNALS OF ONCOLOGY,32,
MLA:
I. Fernandez-Miranda,et al."Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial".ANNALS OF ONCOLOGY 32.(2021):S775-S776